Deep Dives
The stuff your doctor
didn’t have time to explain.
The stuff they may not know.
Each topic goes past the surface into the actual mechanism, the actual research, and the honest gaps in what we know. Bring any of it to your doctor. That is the point.
ATP and Mitochondrial Restoration
If you have mold illness and you are getting worse on treatment, or just not getting better, the answer is probably here. Mycotoxins don’t just make you feel sick. They damage the part of your cells that produces energy. When that goes, everything downstream goes with it, including your ability to detox the toxins that are damaging it. This piece explains that loop and what breaks it.
Protocol Landscape
You’ve probably already been through at least one approach that wasn’t right for you. Before you try the next thing, it helps to understand what each existing framework actually addresses, what it assumes, and where those assumptions break down. This isn’t an attack on any protocol. It’s an honest map of where each one starts to fail, especially for complex or treatment-resistant patients.
Antifungal Strategy
Pharmaceutical antifungals, botanical antifungals, biofilm disruption, and why it matters which one you choose and when. Includes the pharmacogenomic case for why the standard first-line antifungal is the wrong choice for a significant subset of patients, and what the evidence actually says about combination approaches.
Mycotoxin Clearance
How mycotoxins move through the body and how they leave it. Binder comparison, probiotic binding mechanisms, glutathione support, and the monitoring question: how do you actually know if clearance is happening. The binder question in particular is more interesting than most protocols treat it, and the answer isn’t always the most expensive or most prescribed option.
Immune Modulation
Thymosin alpha-1 has been studied for decades, is used clinically in over 35 countries, and most US practitioners have never heard of it. This piece covers it alongside lactoferrin, allicin, mast cell stabilization, and the immune layer that most mold illness protocols underaddress. Immune restoration isn’t a finishing touch. For active infection, it’s the other half of the fight.
EDS and Mold Illness
If you have Ehlers-Danlos Syndrome and mold illness, you already know that every standard protocol treats you like a problem it wasn’t designed to solve. This piece is specifically for you. How connective tissue disorders change the risk calculation for antifungals, surgery, and drug tolerability. One of the only resources on this intersection that exists anywhere.
What every piece includes
The same standard applied to every topic, so you always know what you’re reading and what its limits are.
Primary citations
Author, journal, year, and PMID or DOI for every factual claim. Verify everything yourself.
Evidence level flagged
In vitro, animal, observational, RCT: we label what kind of evidence each claim rests on.
Honest about gaps
When we are extrapolating from mechanism rather than clinical trials, we say so.
Publicly correctable
Every piece is subject to correction. Wrong things get fixed and logged in the public changelog.
No commercial agenda
No affiliate links. No partnerships. Generic names only. Source from wherever makes sense.
Not medical advice
Information to bring to a qualified practitioner. Not instructions to follow independently.
If you read one piece, make it the ATP one.
The ATP piece is where this site starts. Every other topic here builds on the foundation it explains. The forum is where to take it from there.